Merus (NASDAQ:MRUS) Receives $82.00 Average Price Target from Brokerages

Merus (NASDAQ:MRUS) has been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the stock, Marketbeat.com reports. Ten research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $82.00.

Several equities research analysts recently commented on MRUS shares. Canaccord Genuity Group raised shares of Merus to a “strong-buy” rating in a research note on Thursday, July 25th. Canaccord Genuity Group restated a “buy” rating and issued a $67.00 price target on shares of Merus in a research note on Thursday, July 25th. Lifesci Capital upgraded Merus to a “strong-buy” rating in a research note on Monday, July 29th. Guggenheim increased their target price on Merus from $93.00 to $111.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Finally, Needham & Company LLC lowered their price target on Merus from $92.00 to $85.00 and set a “buy” rating for the company in a research report on Monday, August 5th.

Institutional Trading of Merus

A number of institutional investors have recently made changes to their positions in MRUS. Allspring Global Investments Holdings LLC purchased a new stake in Merus during the first quarter valued at $72,000. nVerses Capital LLC boosted its position in Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 1,500 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Merus during the 1st quarter valued at about $108,000. Farallon Capital Management LLC purchased a new stake in shares of Merus during the 2nd quarter valued at about $237,000. Finally, ProShare Advisors LLC bought a new stake in Merus during the second quarter valued at approximately $242,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Stock Up 1.9 %

MRUS opened at $52.30 on Monday. Merus has a 52 week low of $19.81 and a 52 week high of $61.61. The stock has a market cap of $3.07 billion, a PE ratio of -18.88 and a beta of 1.11. The business has a 50 day moving average of $50.85 and a 200-day moving average of $50.56.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.05). The firm had revenue of $7.33 million for the quarter, compared to analysts’ expectations of $9.64 million. Merus had a negative net margin of 476.41% and a negative return on equity of 36.33%. Equities analysts anticipate that Merus will post -3.27 EPS for the current year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.